674 related articles for article (PubMed ID: 14530799)
1. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
4. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
5. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
6. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
7. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
[TBL] [Abstract][Full Text] [Related]
11. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
Koch HJ; Szecsey A; Haen E
Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
[TBL] [Abstract][Full Text] [Related]
12. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
Kato T
Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):145-51. PubMed ID: 15333987
[TBL] [Abstract][Full Text] [Related]
13. NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy.
Kabir MT; Sufian MA; Uddin MS; Begum MM; Akhter S; Islam A; Mathew B; Islam MS; Amran MS; Md Ashraf G
Curr Pharm Des; 2019; 25(33):3506-3518. PubMed ID: 31604413
[TBL] [Abstract][Full Text] [Related]
14. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Farlow MR
Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
[TBL] [Abstract][Full Text] [Related]
15. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
16. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
17. Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
Koch HJ; Uyanik G; Fischer-Barnicol D
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):499-506. PubMed ID: 16266284
[TBL] [Abstract][Full Text] [Related]
18. What is the rationale for new treatment strategies in Alzheimer's disease?
Rogawski MA
CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
[TBL] [Abstract][Full Text] [Related]
19. Classics in Chemical Neuroscience: Memantine.
Alam S; Lingenfelter KS; Bender AM; Lindsley CW
ACS Chem Neurosci; 2017 Sep; 8(9):1823-1829. PubMed ID: 28737885
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
